|
||
| |||||||
|
|
ST. LOUIS, MO,
31st May 2006 -
Sigma-Aldrich (Nasdaq: SIAL), a leading $1.7 billion Life
Science company, is pleased to announce MOgene, LC as its first service
provider of the GenomePlex®
Whole Genome Amplification (WGA) technology. This follows a recent licensing
agreement with Rubicon Genomics, allowing Sigma to offer GenomePlex Whole
Genome Amplification kits to service providers (http://sigma-aldrich.com/wgatechnology).
"We are pleased to be working with MOgene on
service opportunities for GenomePlex WGA," said Keith Jolliff, Director of
Strategic Marketing at Sigma- Aldrich. "Their expertise in reproducible
genetic processing and experimental design will enable further enhancement of
our GenomePlex product line and allow both companies to expand their customer
base."
MOgene, LC is an Agilent certified services
provider for microarray-based gene expression and Comparative Genomic
Hybridization (CGH), currently offering high content, Agilent pre-printed,
catalog microarrays for gene expression analysis. By expanding its service to
include Whole Genome Amplification, MOgene is able to provide a complete
solution to the customer's gene expression workflow. The GenomePlex system
offers unbiased amplification of DNA from any starting material, including
single cells and Formalin-fixed, Paraffin-embedded (FFPE) tissue.
"We offer the highest quality microarray service
to customers eager to make use of Agilent's highly sensitive 60-mer
oligonucleotide format," said Shaukat Rangwala, VP of MOgene's Research
operations. "The partnership with Sigma-Aldrich for Whole Genome Amplification
shows their confidence in our capabilities and allows MOgene to further serve
our customers in the area of CGH, where samples are often limited."
In 2004, Sigma announced an exclusive licensing
agreement with Rubicon to further develop and commercialize the GenomePlex WGA
technology, a highly sensitive, accurate, and proprietary method of amplifying
genomic DNA from any organism. Sigma's success with the GenomePlex technology
has led to the development of several kits offering robust and accurate
amplification. The latest addition to the GenomePlex family of products is the
Single Cell WGA Kit, which supports whole genome amplification from a single
cell resulting in a million-fold amplification of genomic DNA.
Learn more about GenomePlex Whole Genome
Amplification at
http://sigma-aldrich.com/wga.
About Sigma-Aldrich:
Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits are
used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in pharmaceutical
and other high technology manufacturing. The Company has customers in life
science companies, university and government institutions, hospitals, and in
industry. Over one million scientists and technologists use its products.
Sigma-Aldrich operates in 35 countries and has 7,000 employees providing
excellent service worldwide. Sigma-Aldrich is committed to Accelerating
Customer Success through Leadership in Life Science, High Technology and
Service. For more information about Sigma-Aldrich, please visit its
award-winning web site at sigma-aldrich.com.
About MOgene, LC:
MOgene, LC is a biotechnology company that is
focused on improving therapeutic index of drugs by subsequent enhancement of
the safety and efficacy profiles of development candidates in agriculture and
human health. MOgene uses a systems biology approach to understand gene
function in the context of biological pathways, to develop assays and
biomarkers for molecular diagnostic solutions that would help address drug
toxicity issues. We also provide microarray service for gene expression and
array-CGH, which includes custom design of arrays, experimental design and
detailed bioinformatics analysis. For more information, visit
http://mogene.com.
Cautionary Statement:
This release contains forward-looking
statements relating to future performance, goals, strategic actions and
initiatives and similar intentions and beliefs and other statements regarding
the Companies' expectations, goals, beliefs, intentions and the like, which
involve assumptions regarding the Companies' operations and conditions in the
markets the Companies serve. The Companies do not undertake any obligation to
update these forward-looking statements.
Media enquiries to Northbank Communications:
Marc Egelhofer, Tel: +44 (0)1260 296505 m.egelhofer@northbankcommunications.com
At Sigma-Aldrich:
Sean Battles, +1-314-286-7616 Tony Favello, +1-314-286-7879 |
|
| ||||||||
